Normal view MARC view ISBD view

COMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USIN G DIFFERENT DISSOLUTION APPARATUSES (Record no. 11135)

MARC details
000 -LEADER
fixed length control field	a
003 - CONTROL NUMBER IDENTIFIER
control field	OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field	20200210105533.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field	200210b xxu\|\|\|\|\| \|\|\|\| 00\| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency	AIKTC-KRRC
Transcribing agency	AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN)	12046
Author	Hashem, Hanan M.
245 ## - TITLE STATEMENT
Title	COMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USIN G DIFFERENT DISSOLUTION APPARATUSES
250 ## - EDITION STATEMENT
Volume, Issue number	Vol.11(9)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc.	M P
Name of publisher, distributor, etc.	Innovare Academic Sciences Pvt Ltd
Year	2019
300 ## - PHYSICAL DESCRIPTION
Pagination	65-72p.
520 ## - SUMMARY, ETC.
Summary, etc.	Objective: <br/>This study was proposed to evaluate and compare the<br/>in vitro<br/> dissolution profiles of six Metformin Hydrochlorid<br/>e (MH) market products. <br/>Methods: <br/>Different dissolution apparatuses (USP apparatus II<br/>, IV and beaker method) were used to evaluate the d<br/>issolution profiles (in phosphate <br/>buffer, pH 6.8) of two immediate release (IR) generi<br/>c products of Metformin Hydrochloride (MH): Cidopha<br/>ge® 1000 mg (G1, Egyptian market) and <br/>Metformin arrow® 1000 mg (G2, French market) with r<br/>espect to the reference products named Glucophage® <br/>850 mg (R1, Egyptian market and R2, <br/>French market). In addition to a generic controlled<br/>-release (CR) product; Cidophage Retard® 850 mg (G3<br/>) versus the reference product; <br/>Glucophage XR® 1000 mg (R3) (both from Egyptian mar<br/>ket). Dissolution efficiency (D. E.) and the simila<br/>rity factor (<br/>f<br/>2<br/>) were calculated. Weight <br/>uniformity, hardness, tablet dimensions and MH conte<br/>nt were measured. <br/>Results: <br/>Results of the three apparatuses showed that MH IR p<br/>roducts studied (reference and generics) did not me<br/>et the 75% USP 30 specifications <br/>for MH dissolved at 30 min. For MH CR products, Gluco<br/>phage XR® did not fulfill the USP release criteria,<br/> while Cidophage Retard® did. USP <br/>apparatus IV revealed the highest sensitivity and d<br/>iscriminative capability. <br/>Conclusion: <br/>Generally, MH IR generics (G1 and G2) might be inter<br/>changeable with the innovator product (Glucophage®)<br/>. However, Cidophage <br/>Retard® might not be interchangeable with Glucophag<br/>e XR®.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN)	4639
Topical term or geographic name entry element	PHARMACEUTICS
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN)	12047
Co-Author	Abdou, Aya R.
773 0# - HOST ITEM ENTRY
International Standard Serial Number	2656-0097
Title	International journal of pharmacy and pharmaceutical science
Place, publisher, and date of publication	Bhopal Innovare Academic Sciences Pvt Ltd
856 ## - ELECTRONIC LOCATION AND ACCESS
URL	https://innovareacademics.in/journals/index.php/ijpps/article/view/34711/20642
Link text	Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme	Dewey Decimal Classification
Koha item type	Articles Abstract Database

Holdings
Withdrawn status	Lost status	Source of classification or shelving scheme	Damaged status	Not for loan	Home library	Current library	Shelving location	Date acquired	Total Checkouts	Barcode	Date last seen	Price effective from	Koha item type
		Dewey Decimal Classification			School of Pharmacy	School of Pharmacy	Archieval Section	10/02/2020		2020875	10/02/2020	10/02/2020	Articles Abstract Database